Drugs and Natural Products Used in COPD

Year 2022, Volume: 6 Issue: 1, 51 - 58, 15.07.2022

Ahmet Karal Hülya Çelik

Abstract

Chronic Obstructive Pulmonary Disease(COPD), with its most generaldefinition, is a disease represent by the formation of inflammation in the air-ways due to harmful particles and bronchoconstriction and irreversible enlargement and destruction of the lung sacs. Factors causing COPD include inhalation of tobacco or tobacco-like substances, environmental exposures, genetic factors, chemicals and air pollution. The drugs used in the treatment of COPD aim to reduce the breathing of patients, acute exacerbations and inflammation. While bronchodilator drugs, which are among the drugs used in treatment, prevent constriction, anti-inflammatory drugs act by reducing inflammation. It is also used in natural products such as ginger, mint and eucalyptus in the treatment ofCOPD. New methods are being improved for the treatment of COPD with the researches and studies conducted in recent years. In addition, new drugs are tried in treatment. More effective methods and drugs continue to be discovered for the treatment of COPD.Early diagnosis is of great importance in the treatment of COPD. Despite these, there is no cure for COPD.

Keywords

COPD, COPD drugs, Natural products

References

• [1]Kalender E. KOAH Hastalarina Eczaci Tarafindan İlaç Eğitimi Verilmesinin Klinik Parametrelere ve Yaşam Kalitesine Etkisinin Değerlendirilmesi [Evaluation of the Effect of Drug Education by Pharmacists on Clinical Parameters and Quality of Life in COPD Patients]. Master Thesis. Ankara University. Ankara (2013).
• [2]Mapp CE, Boschetto P, Maestrelli P, Fabbri LM. Occupational Asthma. Am. J. Respir. Crit. Care Med(2005) 172(3):280–305. doi:10.1164/rccm.200311-1575SO.
• [3]KOAH Nasıl Tedavi Edilir? [How to Cure COPD?](2022). Available from: https://www.koahhastalaridernegi.org/.
• [4]Arseven O, Öngen G, Müsellim B, Okumuş G. Türkiye’de Temel Akciğer Sağlığı Sorunları ve Çözüm Önerileri[Basic Lung Health Problems in Turkey and Solution Suggestions](2010).
• [5]Vestbo J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease GOLD executive summary. Am. J. Respir. Crit. Care Med(2013) 187(4):347–365. doi:10.1164/rccm.201204-0596PP.
• [6]Günay S, Sariaydin M, Demırcı N. KOAH tedavisinde yeni bronkodilatörler ve kombinasyonları [New bronchodilators and their combinations in the treatment of COPD]. Tuberk. Toraks(2016) 64(3):240–245. doi:10.5578/tt.10267.
• [7]Tekin E, Bayraktar M, Sanalp Menekşe T, Bayramoğlu A. Treatment Management in Acute Exacerbation of COPD in the Emergency Department: Dilemma in Oxygen Therapy. International Journal of Innovative Research and Reviews(2020) 4(2):23–29.[8]Almadhoun K, Sharma S. Bronchodilators. StatPearls(2021).
• [9]Higgins BG, Powell RM, Cooper S, Tattersfield AE. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur. Respir. J(1991) 4(4):415–420.
• [10]Salbutamol,” National Center for Biotechnology Information(2020). Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Salbutamol.[11]Morgan D, Paull J, Richmond B, Wilson‐Evered E, Ziccone S. Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br. J. Clin. Pharmacol(1986) 22(5):587–593. doi:10.1111/j.1365-2125.1986.tb02939.x.
• [12]Fenoterol in Turkish. Fenoterol in Türkiye(2022). [13]Levalbuterol,” National Library of Medicine National Center for Biotechnology InformationPubChem CID 123600. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Levalbuterol.
• [14]Levalbuterol CONCENTRATE Vial For Nebulizer -Uses, Side Effects, and More. WebMD(XXXX).
• [15]Cooperberg A, Breckenridge SM, ArbelaezAM, Cryer PE. Terbutaline and the Prevention of Nocturnal Hypoglycemia in Type 1 Diabetes(2008). doi:10.2337/dc08-0520.
• [16]Riether C. Stimulation of β2-adrenergic receptors inhibits calcineurin activity in CD4+ T cells via PKA-AKAP interaction. Brain. Behav. Immun(2011) 25(1):59–66. doi:10.1016/j.bbi.2010.07.248.
• [17]Anderson G. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator. Life Sci(1993) 52(ue 26):2145–2160. doi:10.1016/0024-3205(93)90729-M.
• [18]Salomon JJ. Beta-2 Adrenergic Agonists Are Substrates and Inhibitors of Human Organic Cation Transporter 1. Mol. Pharm(2015) 12(8):2633–2641. doi:10.1021/mp500854e.
• [19]Hanania NA. The safety andefficacy of arformoterol and formoterol in COPD. COPD J. Chronic Obstr. Pulm. Dis(2010) 7(1):17–31. doi:10.3109/15412550903499498.
• [20]Donohue JF. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: A one year evaluation of safety and tolerance. Ther. Adv. Respir. Dis(2008) 2(2):37–48. doi:10.1177/1753465808089455.
• [21]P. L, C R, Kagan M, Dain J. Metabolism and Pharmacokinetics of Indacaterol in Humans. Drug Metab. Dispos. Sept(2012) 40(9):1712–1722. doi:10.1124/dmd.112.046151.
• [22]Naline E, Trifilieff A, Fairhurst RA, Advenier C, Molimard M. Effect of indacaterol, a novel long-acting β2-agonist, on isolated human bronchi. Eur. Respir. J(2007) 29(3):575–581. doi:10.1183/09031936.00032806.
• [23]Deeks ED. Olodaterol: A review of its use in chronic obstructive pulmonary disease. Drugs(2015) 75(6):665–673. doi:10.1007/s40265-015-0371-4.
• [24]Koch A. International Journal of COPD Dovepress Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat ® versus placebo and formoterol twice daily in patients with gOlD 2-4 COPD: results from two replicate 48-week studies(2014). doi:10.2147/COPD.S62502.
• [25]Cazzola M, Testi R, Matera MG. of Salmeterol. Drug Dispos(2002) 41(1):19–30. [26]Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am. J. Med. Suppl(2004) 117(12):24–32. doi:10.1016/j.amjmed.2004.10.018.
• [27]Gross NJ. Anticholinergic agents in asthma and COPD. Eur. J. Pharmacol(2006) 533(1–3):36–39. doi:10.1016/j.ejphar.2005.12.072.
• [28]Drugbank. Ipratropium. Available from: https://go.drugbank.com/drugs/DB00332.
• [29]Ipratropium Bromide (Code C29128: NCI Metathesaurus. [30]Rehder KJ. Adjunct therapies for refractory status asthmaticus in children. Respir. Care(2017) 62(6):849–865. doi:10.4187/respcare.05174.
• [31]Oxitropium bromide. Wikipedia(2022). [32]Frith C, A. P, Jenner B, Dangerfield R, Atkinson J, Drennan. Oxitropium bromide: dose-response and time-response study of a new anticholinergic bronchodilator drug. Chest(1986) 89(2):249–253. doi:10.1378/chest.89.2.249.
• [33]Aclidinium. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548832/. doi:Liver.
• [34]Cazzola M, Mario CP. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opin. Pharmacother(2013) 14(9):1205–1214.[35]Glycopyrronium. DrugBank.
• [36]Price F, D. S, A., Cerasoli. Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients. Expert Opin. Drug Metab. Toxicol(2009) 5(4):417–424. doi:10.1517/17425250902828337.
• [37]Tiotropium Bromide (Code C84608. In: NCI Metathesaurus. CL449040. [38]Decramer M. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir. Physiol. Neurobiol(2013) 185(2). doi:10.1016/j.resp.2012.08.022.
• [39]Incalzi RA, Gemma A, Marra C, Muzzolon R, Capparella O, Carbonin P. Chronic obstructive pulmonary disease: An original model of cognitive decline. Am. Rev. Respir. Dis(1993) 148(2):418–424. doi:10.1164/ajrccm/148.2.418.
• [40]İlvan A. Kronik Obstrüktif Akciğer Hastalığı Alevlenmesinde Farmakolojik Tedavi [Pharmacological Treatment in Chronic Obstructive Pulmonary Disease Exacerbation]. Solunum Dergisi(2009) 0(324):14–17. [41]Theophylline (Code C872. NCI MetathesaurusC0039771.
• [42]Aminophylline. National Library of Medicine National Center for Biotechnology Information(2022). [43]Anti-inflammatory(2022). Available from: https://tr.wikipedia.org/static/images/mobile/copyright/wikipedia-wordmark-tr.svg,
• [44]Cazzola M, Page CP, Calzetta L, Matera MG. Emerging anti-inflammatory strategies for COPD. Eur. Respir. J(2012) 40(3):724–741. doi:10.1183/09031936.00213711.
• [45]V. J, Loukides D, Bartziokas K. Novel Anti-Inflammatory Agents in COPD: Targeting Lung and Systemic Inflammation14(2013). 235–245. doi:10.2174/1389450111314020008.
• [46]Sezer L, Kart M. KOAH tedavisinde inhale kortikosteroidler [Inhaled corticosteroids in the treatment of COPD](2013). 24–30.
• [47]Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin. Sci94(6):557–572. doi:10.1042/cs0940557.
• [48]Fluticasone: National Institutes of Health National Library of Medicine National Center for Biotechnology Information (2022).
• [49]F. I. Jadwiga A. Wedzicha, M.D., M.D. DB, M.D. KR, M.D. JV, M.D. D, Nicolas Roche MD, et al. Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD. N Engl JMed(2016) 374:2222–2234. doi:10.1056/NEJMoa1516385.
• [50]Budesonide: National Institutes of Health National Library of Medicine National Center for Biotechnology Information (2022).
• [51]Roth A, G. W, A. N, L., Thalén. High-performance liquid chromatographic determination of epimers, impurities, and content of the glucocorticoid budesonide and preparation of primary standard. J. Pharm. Sci(1980) 69(7):766–770. doi:10.1002/jps.2600690705. [52]Prednisolone for COPD: COPD NEWS TODAY (2022).
• [53]Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br. J. Pharmacol(2011) 163(1):53–67. doi:10.1111/j.1476-5381.2011.01218.x.[54]Roflumilast. Available from: https://go.drugbank.com/drugs/DB01656. doi:Online.
• [55]Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet(2009) 374(9691):685–694. doi:10.1016/S0140-6736(09)61255-1.
• [56]Cilomilast. Available from: https://go.drugbank.com/drugs/DB03849. doi:online.
• [57]Turkish Medicines and Medical Devices Agency, Department of Rational Drug Use. Antibiyotik Nedir ? [What is antibiotic?](2022). Available from: http://www.akilciilac.gov.tr/?page_id=1009.
• [58]Sayıner L, A. M. Türk Toraks Derneği akut bronşit ve KOAH ve bronşektazi alevlenmelerinde antibiyotik tedavisi uzlaşı raporu [Turkish Thoracic Society Consensus Report on Antibiotic Treatment in Acute Bronchitis and COPD and Bronchiectasis Exacerbations]. Türk Toraks Derg(2009) 10(7):3–7.
• [59]Bakır M. Günümüzde KOAH Akut Alevlenmelerinde Antibiyotik Seçimi [Antibiotic Choice in Acute Exacerbations of COPD Today]. Flora(2003) 8.
• [60]Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest(1995) 108(2 SUPPL):43–52. doi:10.1378/chest.108.2_Supplement.43S.
• [61]Erdosteine. DrugBank. [62]Sadowska AM, Verbraecken J, Darquennes K, Backer W. The role for N-acetylcysteine in the management of COPD. Int. J. Chron. Obstruct. Pulmon. Dis(2006) 1(2):425–434. doi:10.2147/copd.2006.1.2.99.
• [63]Bastos V. Inhaled 1,8-cineole reduces inflammatory parameters in airways of ovalbumin-challenged guinea pigs. Basic Clin. Pharmacol. Toxicol(2011) 108(1):34–39. doi:10.1111/j.1742-7843.2010.00622.x.
• [64]Worth H, Schacher C, Dethlefsen U. Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: A placebo-controlled double-blind trial. Respir. Res(2009) 10:1–7. doi:10.1186/1465-9921-10-69.
• [65]Çifci A. Ginger (Zingiber officinale) prevents severe damage to the lungs due to hyperoxia and inflammation. Turkish J. Med. Sci(2018) 48(4):892–900. doi:10.3906/sag-1803-223.
• [66]GREEN RJ. Natural therapies for emphysema and COPD: relief and healing for chronic pulmonary disorders: Inner Traditions/Bear & Co (2007).
• [67]McKay DL, B J. IA Review of the Bioactivity and Potential Health Benefits of Peppermint Tea (Mentha piperita L. Phyther. Res(2006) 20:619–633. doi:10.1002/ptr.1936.
• [68]Scaglione F, Weiser K, Alessandria M. Effects of the standardised ginseng extract G115® in patients with chronic bronchitis: A nonblinded, randomised, comparative pilot study. Clin. Drug Investig(2001) 21(1):41–45. doi:10.2165/00044011-200121010-00006.
• [69]Eo SK, Kim YS, Lee CK, Han SS. Antiviral activities of various water and methanol soluble substances isolated from Ganoderma lucidum. J. Ethnopharmacol(1999) 68(1–3):129–136. doi:10.1016/S0378-8741(99)00067-7.
• [70]Isbaniah F,Wiyono WH, Yunus F, Setiawati A, Totzke U, Verbruggen MA. Echinacea purpurea along with zinc, selenium and vitamin C to alleviate exacerbations of chronic obstructive pulmonary disease: Results from a randomized controlled trial. J. Clin. Pharm. Ther(2011) 36(5):568–576. doi:10.1111/j.1365-2710.2010.01212.x.